{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=25", "query": { "intervention": "rituximab", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 1303, "total_pages": 131, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T23:34:08.111Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04002401", "title": "Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-11-05", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Duarte, California • Palo Alto, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04002401" }, { "nct_id": "NCT05453500", "title": "Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-03-27", "completion_date": "2031-05-01", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453500" }, { "nct_id": "NCT00006436", "title": "EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, AIDS-related", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "EPOCH", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2001-01-29", "completion_date": "2024-01-18", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006436" }, { "nct_id": "NCT03064867", "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell-lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-06-26", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 3, "location_summary": "St Louis, Missouri • Cleveland, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064867" }, { "nct_id": "NCT00636792", "title": "A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "VELCADE", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2008-02", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-01-13", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bismarck, North Dakota", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bismarck", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00636792" }, { "nct_id": "NCT02532257", "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "CD20 Positive", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2016-04-11", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532257" }, { "nct_id": "NCT00521014", "title": "GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 14, "start_date": "2007-10", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-12-22", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00521014" }, { "nct_id": "NCT00582816", "title": "Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Solid Tumors" ], "interventions": [ { "name": "Clinimacs Cell Separation System", "type": "DEVICE" }, { "name": "conditioning chemotherapy", "type": "DRUG" }, { "name": "DLI", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "DRUG", "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 9, "start_date": "2008-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582816" }, { "nct_id": "NCT07588698", "title": "Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's B-cell Lymphoma", "Lymphoma Non-Hodgkin", "Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP)", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Blood specimen collection", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Computerized tomography (CT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "Carrie Ho, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-11-15", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07588698" }, { "nct_id": "NCT00486421", "title": "Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Nonneoplastic Condition" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 22, "start_date": "2007-01", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2014-10-17", "last_synced_at": "2026-10-25T23:34:08.111Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00486421" } ] }